Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) funded clinical trial evaluating MASL in patients with oral squamous cell carcinoma (OSCC).